Lyell Immunopharma (LYEL) Interest Expenses (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Interest Expenses data on file, last reported at $58.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 17.76% year-over-year to $58.7 million; the trailing twelve-month figure through Mar 2026 stood at $58.7 million (down 17.76% YoY), and the FY2025 full-year result was $17.1 million, down 95.25% from the prior year.
• Interest Expenses climbed to $58.7 million in Q1 2026, from $17.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $359.4 million in Q4 2024 to a low of $12.2 million in Q3 2023.
• A 5-year average of $95.1 million and a median of $71.4 million in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 960.16% in 2022 and plunged 95.25% in 2025, its largest moves.
• Tracing LYEL's Interest Expenses over 5 years: stood at $180.1 million in 2022, then jumped by 37.91% to $248.4 million in 2023, then soared by 44.69% to $359.4 million in 2024, then sank by 95.25% to $17.1 million in 2025, then soared by 243.5% to $58.7 million in 2026.
• Business Quant data shows LYEL's Interest Expenses at $58.7 million in Q1 2026, $17.1 million in Q4 2025, and $65.1 million in Q3 2025.